- CANDID-CNS TM achieves an 83% success rate for predicting small molecule brain penetration and distribution versus a 64% success rate for the industry standard CNS-MPO score - Only ~2% of small ...
1910's CANDID-CNS™ AI model has been published in the Journal of Chemical Information and Modeling (JCIM), a journal of the American Chemical Society. CANDID-CNS™ is the new state-of-the-art AI model ...
COYA 303 is an investigational proprietary combination of LD-IL-2 and GLP-1RA for subcutaneous administration, under development for the treatment of diseases, including Alzheimer's Disease, driven by ...
Figure 1: Prof. LIU Kai (first right, front row) from the Division of Life Science and Department of Chemical and Biological Engineering and his research team, alongside with Prof. WANG Yiwen (first ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. CANDID-CNS™ distinguishes CNS penetrant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results